Literature DB >> 4395528

On the mode of action of amantadine.

U Stromberg, T H Svensson, B Waldeck.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4395528     DOI: 10.1111/j.2042-7158.1970.tb08487.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


× No keyword cloud information.
  17 in total

Review 1.  Requiem for "Schizophrenia".

Authors:  J S Howard
Journal:  Integr Physiol Behav Sci       Date:  1996 Apr-Jun

2.  Neuroleptic malignant syndrome successfully treated with amantidine.

Authors:  J Woo; R Teoh; J Vallance-Owen
Journal:  Postgrad Med J       Date:  1986-08       Impact factor: 2.401

Review 3.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

Review 4.  Antiparkinsonian drugs: pharmacological and therapeutic aspects.

Authors:  D B Calne; J L Reid
Journal:  Drugs       Date:  1972       Impact factor: 9.546

5.  Interactions of L-dopa and amantadine in patients with Parkinsonism.

Authors:  B Cox; G Danta; H Schnieden; G M Yuill
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-06       Impact factor: 10.154

6.  Proceedings: Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and parkinsonian subjects.

Authors:  D G Jones; J A Lenman; M A Robertson; M J Turnbull
Journal:  Br J Pharmacol       Date:  1972-02       Impact factor: 8.739

7.  Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.

Authors:  J D Parkes; R C Baxter; C D Marsden; J E Rees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-04       Impact factor: 10.154

8.  In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M. Parkinson.

Authors:  W Wesemann; G Dette-Wildenhahn; H Fellehner
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

9.  Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study.

Authors:  A Barbeau; H Mars; M I Botez; M Joubert
Journal:  Can Med Assoc J       Date:  1971-07-10       Impact factor: 8.262

10.  Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect.

Authors:  G M Pacifici; M Nardini; P Ferrari; R Latini; C Fieschi; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.